October 31, 2014 3:26 PM ET

Pharmaceuticals

Company Overview of Trigemina, Inc.

Company Overview

Trigemina, Inc. develops non-opiate drug formulations and delivery systems for the pain therapy. The company’s products include TI-001, an intranasal oxytocin that targets chronic and sub-acute head pain; and TI-002, a non-opioid treatment that addresses a range of pain, including neuropathic pain throughout the body. Its drugs are delivered via the nasal-cerebral pathway. The company was founded in 2006 and is based in Mountain View, California.

809-B Cuesta Drive

Suite 109

Mountain View, CA 94040

United States

Founded in 2006

Phone:

650-303-6140

Fax:

650-938-0898

Key Executives for Trigemina, Inc.

Chief Executive Officer
Co-Founder
Founder and Director
Founder and Chief Scientist
Co-Founder
Compensation as of Fiscal Year 2014.

Trigemina, Inc. Key Developments

Trigemina, Inc. Presents at 9th Annual The Neurotech Investing & Partnering Conference 2014, Apr-23-2014 03:30 PM

Trigemina, Inc. Presents at 9th Annual The Neurotech Investing & Partnering Conference 2014, Apr-23-2014 03:30 PM. Venue: The Ritz Carlton, 10 Avery St., Boston, Massachusetts, United States. Speakers: Charles Yeomans, Chief Executive Officer, President and Director.

Trigemina, Inc. Announces Expansion of Phase II Study of TI-001 for Chronic Migraine

Trigemina, Inc. announced it has expanded its phase II clinical study for TI-001, intranasal oxytocin, beyond Chile to include sites in Brisbane and Adelaide, Australia. The company announced that the expansion of the Phase II study to centers in Australia demonstrates the increasing excitement and support throughout the international community in addressing one of the most urgent global needs in drug development: a safe and effective therapy for chronic migraine. This progress will place the company on track to complete enrollment of the trial in the second half of 2014. The phase II TRIG-05 study is evaluating TI-001, an investigational, nasally-delivered oxytocin therapeutic being examined to determine its efficacy, tolerability, and safety in chronic migraine patients. Secondary endpoints in this study include determining the Phase III dosage and exploring interlukin-6 (IL-6) levels as a potential biomarker for predicting efficacy. The TRIG-05 study is a placebo-controlled, double-blind, randomized-withdrawal and enrollment enriched clinical trial expected to enroll 96 patients. If approved by the U.S. Food and Drug Administration (FDA), TI-001 could be the first non-invasive treatment approved for chronic migraine, a debilitating condition affecting more than six million Americans.

Trigemina, Inc. Initiates Phase II Clinical Trial of TI-001 for Chronic Migraine

Trigemina, Inc. announced the initiation of their Phase II clinical study investigating the use of TI-001, intranasal oxytocin, for the treatment of chronic migraine. The placebo-controlled, double-blind, randomized-withdrawal and enrollment enriched study, TRIG-05, officially began its enrollment period on May 31, 2013, and is expected to enroll 96 chronic migraine patients at trial sites located in Chile, with additional sites in Argentina expected to join in July. The first patient was enrolled in the study and treated on June 6, 2013. The primary clinical endpoint of the study is to demonstrate efficacy, tolerability and safety of TI-001, with the secondary goal of determining the best Phase III dosage and exploring interlukin-6 (IL-6) levels as a potential biomarker for predicting efficacy. If approved by the U.S. Food and Drug Administration (FDA), TI-001 could be the first non-invasive treatment approved for chronic migraine, a debilitating condition affecting more than six million Americans.

Similar Private Companies By Industry

Company Name Region
CNS Therapeutics, Inc. United States
Merz North America, Inc. United States
Kalos Therapeutics, Inc. United States
Comsort, Inc. United States
Bachem, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Trigemina, Inc., please visit trigemina.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.